Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C

COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that final results of three large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding questions in the hepatitis C research community and provide important insights. The results of the studies, involving a total of more than 2,700 patients, were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting.

"Physicians are constantly looking for ways to improve hepatitis C treatment outcomes by increasing response rates or reducing side effects and making treatment more tolerable for their patients," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "We undertook these large PEGINTRON studies to help investigators address these important clinical issues. Conducting these studies demonstrates Schering-Plough's longstanding commitment to investigating potential new treatment strategies for patients with hepatitis C."

Combination therapy with peginterferon and ribavirin is a recognized standard of care worldwide for treating chronic hepatitis C virus (HCV) infection. Patients with HCV genotype 1, the most common and hardest to treat form of hepatitis C, are typically treated for 48 weeks, while patients with HCV genotypes 2 or 3 are treated for 24 weeks.

The aim of the three PEGINTRON studies was to evaluate investigational regimens in these patient populations compared to current standard practice.

Key Findings

PEGINTRON Maintenance Therapy in Cirrhotic (Metavir F4) HCV Patients Who Failed to Respond to Interferon
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... -- The Pharmaceutical Care Management Association (PCMA) issued ... offsets included in the Energy & Commerce Committee,s ... 21st Century Cures initiative can only be advanced by ... Medicare – then its costs outweigh any potential ... "Leveraging payments to Part D plans to ...
(Date:5/21/2015)...  Heidrick & Struggles (Nasdaq: HSII ), the ... consulting and culture shaping worldwide, strengthens ... announcing the addition of Tim Dietlin to ... Dietlin has extensive life sciences and professional ... Medical and Commercial functions to increase productivity, drive transformational ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 Research ... announced the addition of the "Global Next ... offering. The global next generation sequencing ... over the period 2014-2019 This report ... of the global next generation sequencing market for ...
Breaking Medicine Technology:Heidrick Increases Healthcare and Life Sciences Expertise 2Global Next Generation Sequencing Market 2015-2019 2
... Annual Meeting- , , ... of a randomized phase III study presented at the ... The study in adult patients with hematological malignancies at ... demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid ...
... Analgesic Significantly Reduces Postop Pain, Opioid Use, and ... Standard Pain Medication , ... A Phase II dose escalation study of a ... who underwent total knee arthroplasty, or TKA, showed ...
Cached Medicine Technology:Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 2Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 3Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 4
(Date:5/22/2015)... 2015 Power Systems is proud to announce ... race season. Drobeck is in his second year of racing ... with the Missoula Fire Department in Missoula, MT. He entered ... 2014. During his career, he has had 15 1st Place ... top 10 finishes in all seven of his 2014 races, ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all ... company specialize in include decks, additions, kitchen remodeling, interior ... much more. , The redesigned logo is a ... company. It includes two geometrical lines that represent the ... to be used with many things associated with the ...
(Date:5/22/2015)... 2015 DMG Productions announces the upcoming ... broadcast on Friday, May 29, 2015 at 7:30 a.m. ... In this episode Innovations will explore Interstate Restoration, a ... quickly through disaster recovery and restoration. , Additionally, the ... collaboratively to develop and deliver training and education in ...
(Date:5/22/2015)... May 22, 2015 Co founders Greenlee and ... to allow general dentists to immediately deliver fully integrated dental ... on that of the medical surgeon. , The Center, ... roadblocks preventing general dentists from placing dental implants. These ... steps to introduce the surgical placement of dental implants into ...
(Date:5/22/2015)... Yisrayl Hawkins, Pastor and Overseer at The ... letter calling on religious leaders to make changes in order ... on his blog, discusses the history of war, how it ... it. Yisrayl says mankind was created to lead peaceful, joyful ... society. , “Yahweh created mankind, according to His Plan, ...
Breaking Medicine News(10 mins):Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2
... Center is one of only 10 pediatric hospitals in the ... U.S.News & World Report,s America,s Best Children,s Hospitals ... serve children, 56 were ranked, and only an elite 10 ... coveted Honor Roll. The specific service lines surveyed included cancer, ...
... three national organizations representing nearly a third of a ... their continued concern for America,s patients who do not ... of Family Physicians (AAFP), the American College of Physicians ... majority of physicians who care for Medicare patients. The ...
... Members of Congress Seek Oncology Best Practices as First Step ... 18 U.S. Representatives Rep. Artur Davis (D-AL), Steve Israel ... the Medicare Quality Cancer Care Demonstration Act of 2009. ... to direct the Centers for Medicare & Medicaid Services (CMS) ...
... ... leadership must be strengthened and expanded at the individual, institutional, and network levels, Accordia ... ... outcomes in Africa over the long term, the continent’s healthcare leadership must be strengthened ...
... treatment of type 2 diabetes is not scientifically proven. Nor ... form, such as metformin and sulfonylureas. As a result, there ... been approved for 10 years and nateglinide for 8 years ... of longer duration than 14 months. This is the conclusion ...
... Nuu Rainforest Spring Water launches in the United States with several ... Appointments have already been set with several major distributors, ... having already approved the line for distribution , ... there is a place where nature shines. The ancient tribe ...
Cached Medicine News:Health News:Children's Named Among the Nation's Top 10 Pediatric Hospitals by U.S.News & World Report 2Health News:Call for primary care reform from AAFP, ACP and AOA 2Health News:Call for primary care reform from AAFP, ACP and AOA 3Health News:Call for primary care reform from AAFP, ACP and AOA 4Health News:House Bill to Provide Cancer Patients With Solution for Quality Cancer Care Within an Equitable Medicare Model 2Health News:House Bill to Provide Cancer Patients With Solution for Quality Cancer Care Within an Equitable Medicare Model 3Health News:House Bill to Provide Cancer Patients With Solution for Quality Cancer Care Within an Equitable Medicare Model 4Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 3Health News:Benefit of glinides is not proven 2Health News:Benefit of glinides is not proven 3Health News:Next Generation Waters - Nuu 2
... Plates feature a unique design for easy ... CP titanium and .3mm thick for ease ... optimal malleability. Universal (left/right) anatomical shape for ... and smooth construction for optimal safety. Four ...
... Brown nucleus cracker with straight shaft ... viscoelastic, thereby, maintains anterior chamber depth ... Accomplished with a design that keeps ... blocking outflow of viscoelastic. Available with ...
Epilation forceps angled ends size 3.5"....
Forceps, delicate, straight....
Medicine Products: